Understand the source comparison
Clinical Trial Outcomes and Head-to-Head Comparisons
Survodutide Dual GLP-1/glucagon agonist 12.5–14.7% Nausea (40%), diarrhea (28%), elevated heart rate (15%) Fastest fat oxidation due to hepatic glucagon signaling. Best for patients who plateau on GLP-1 monotherapy Mazdutide GLP-1/GIP co-agonist 11.8–13.2% Nau
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- Dual GLP-1/glucagon agonist
- 12.5–14.7%
- Nausea (40%), diarrhea (28%), elevated heart rate (15%)
- Fastest fat oxidation due to hepatic glucagon signaling. Best for patients who plateau on GLP-1 monotherapy
- Mazdutide
- GLP-1/GIP co-agonist
- 11.8–13.2%
- Nausea (35%), injection site reactions (18%)
- GIP agonism adds thermogenic benefit without cardiovascular risk seen in tesofensine
- Tesofensine
- Triple monoamine reuptake inhibitor
- 10.6–12.8%
- Heart rate elevation (25%), insomnia (22%), dry mouth (30%)
- Non-incretin mechanism allows combination with GLP-1 agonists, but cardiovascular contraindications limit eligibility
- Tirzepatide
- GLP-1/GIP dual agonist
- 15–22.5% (SURMOUNT-1 trial)
- Nausea (30%), vomiting (12%), diarrhea (20%)
- FDA-approved as Mounjaro and Zepbound. Strongest clinical evidence but slower onset than survodutide
- Semaglutide
- GLP-1 receptor agonist
- 14.9% (STEP-1 trial)
- Nausea (44%), constipation (24%), gallbladder events (1.5%)
- Gold standard for safety profile. Lower adverse event discontinuation rate than dual agonists
- Tirzepatide technically outperforms survodutide in total weight loss percentage, but the SURMOUNT-1 trial ran 72 weeks versus survodutide's 46-week trials. When adjusted for time, survodutide shows faster monthly fat loss velocity. The tradeoff is adverse event frequency: dual-action compounds cause nausea in 35–45% of users during titration compared to 20–30% for GLP-1 monotherapy. Patients who can't tolerate tirzepatide or survodutide often succeed on semaglutide or mazdutide by extending the titration period from 12 weeks to 20 weeks.